Piper Sandler initiates CareDx stock coverage with overweight rating
Piper Sandler initiated coverage on CareDx (CDNA) with an overweight rating and $100 price target, citing growth potential. The stock trades at $80.77, up 382% over the past year. The firm expects mid-teens to 20% growth in transplant business and 30%-40% annual growth for NavDx. CareDx reported Q3 2026 earnings of $0.70 EPS and $139M revenue, raising its full-year outlook. BTIG and Canaccord also raised their price targets to $92 and $99, respectively, maintaining Buy ratings.
How this was made
The 30-second read
Why it matters
The new coverage and price target provide a fresh catalyst that could move the stock higher in the near term.
Market read
Analyst initiation is a primary news event for CDNA, likely influencing short‑term trading decisions.
What to watch
Potential regulatory or reimbursement risks in transplant testing not addressed.
Background
CareDx recently posted strong Q3 2026 results, beating expectations and raising guidance, prompting analyst upgrades.
Ticker impact
Piper Sandler initiated coverage on CareDx with an overweight rating and a $100 price target, a new analyst recommendation for the stock.
potential upside as investors price in the new rating and target
The rating and target are fresh, providing a concrete catalyst for short‑term buying pressure.
Market effects
May lift sentiment in the transplant diagnostics sector as peers could be re‑rated.
Limited to US biotech/healthcare investors.
Low, confined to niche market participants.
Counterpoint
The rating could be premature if growth assumptions prove optimistic.
Key entities
- AnalystPiper Sandler
Initiated coverage with overweight rating and $100 target.
- CompanyCareDx, Inc.
NASDAQ‑listed provider of transplant diagnostic testing.



